Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Arrowhead (ARWR) announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for ...

World RNAi Market 2010Contract service = outsourced research/target validation projects Total = Projected worldwide RNAi revenues for 2010, in US dollars Source: Frost & SullivanScientists hunger for ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) ...

PHILADELPHIA, PA—Zilebesiran (Alnylam), an investigational therapeutic agent that interferes with messenger RNA to stop the production of angiotensinogen (AGT), lowers systolic blood pressure levels ...

RNA interference (RNAi) offers a fast and easy system to study gene functions. However, the traditionally used small interfering RNAs (siRNAs) can exhibit pronounced and problematic off-target effects ...